Cited 10 times in
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 천재희 | - |
dc.date.accessioned | 2022-12-22T01:26:59Z | - |
dc.date.available | 2022-12-22T01:26:59Z | - |
dc.date.issued | 2022-02 | - |
dc.identifier.issn | * | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191224 | - |
dc.description.abstract | Objectives: 5-aminosalicylate (mesalazine; 5-ASA) is an established first-line treatment for mild-to-moderate ulcerative colitis (UC). This study aimed to model the benefits of optimising 5-ASA therapy. Methods: A decision tree model followed 10 000 newly diagnosed patients with mild-to-moderately active UC through induction and 1 year of maintenance treatment. Optimised treatment (maximising dose of 5-ASA and use of combined oral and rectal therapy before treatment escalation) was compared with standard treatment (standard doses of 5-ASA without optimisation). Modelled data were derived from published meta-analyses. The primary outcomes were patient numbers achieving and maintaining remission, with an analysis of treatment costs for each strategy conducted as a secondary outcome (using UK reference costs). Results: During induction, there was a 39% increase in patients achieving remission through the optimised pathway without requiring systemic steroids and/or biologics (6565 vs 4725 for standard). Potential steroidal/biological adverse events avoided included: seven venous thromboembolisms and eight serious infections. Out of the 6565 patients entering maintenance following successful induction on 5-ASA, there was a 21% reduction in relapses when optimised (1830 vs 2311 for standard). This translated into 297 patients avoiding further systemic steroids and 214 biologics. Optimisation led to an average net saving of £272 per patient entering the model for the induction and maintenance of remission over 1 year. Conclusion: Modelling suggests that optimising 5-ASA therapy (both the inclusion of rectal 5-ASA into a combined oral and rectal regimen and maximisation of 5-ASA dose) has clinical and cost benefits that supports wider adoption in clinical practice. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | BMJ Publishing Group Ltd | - |
dc.relation.isPartOf | BMJ OPEN GASTROENTEROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Administration, Oral | - |
dc.subject.MESH | Anti-Inflammatory Agents, Non-Steroidal / adverse effects | - |
dc.subject.MESH | Anti-Inflammatory Agents, Non-Steroidal / therapeutic use | - |
dc.subject.MESH | Biological Products* / therapeutic use | - |
dc.subject.MESH | Colitis, Ulcerative* / chemically induced | - |
dc.subject.MESH | Colitis, Ulcerative* / drug therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Mesalamine / adverse effects | - |
dc.subject.MESH | Mesalamine / therapeutic use | - |
dc.subject.MESH | Neoplasm Recurrence, Local / chemically induced | - |
dc.subject.MESH | Neoplasm Recurrence, Local / drug therapy | - |
dc.subject.MESH | Remission Induction | - |
dc.subject.MESH | Sulfasalazine / adverse effects | - |
dc.title | Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Edouard Louis | - |
dc.contributor.googleauthor | Kristine Paridaens | - |
dc.contributor.googleauthor | Sameer Al Awadhi | - |
dc.contributor.googleauthor | Jakob Begun | - |
dc.contributor.googleauthor | Jae Hee Cheon | - |
dc.contributor.googleauthor | Axel U Dignass | - |
dc.contributor.googleauthor | Fernando Magro | - |
dc.contributor.googleauthor | Juan Ricardo Márquez | - |
dc.contributor.googleauthor | Alexander R Moschen | - |
dc.contributor.googleauthor | Neeraj Narula | - |
dc.contributor.googleauthor | Grazyna Rydzewska | - |
dc.contributor.googleauthor | Matthew J Freddi | - |
dc.contributor.googleauthor | Simon Pl Travis | - |
dc.identifier.doi | 10.1136/bmjgast-2021-000853 | - |
dc.contributor.localId | A04030 | - |
dc.relation.journalcode | J04336 | - |
dc.identifier.eissn | 2054-4774 | - |
dc.identifier.pmid | 35165124 | - |
dc.subject.keyword | 5-aminosalicylic acid (5-asa) | - |
dc.subject.keyword | inflammatory bowel disease | - |
dc.subject.keyword | ulcerative colitis | - |
dc.contributor.alternativeName | Cheon, Jae Hee | - |
dc.contributor.affiliatedAuthor | 천재희 | - |
dc.citation.volume | 9 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | e000853 | - |
dc.identifier.bibliographicCitation | BMJ OPEN GASTROENTEROLOGY, Vol.9(1) : e000853, 2022-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.